Medtronic, a leader in healthcare technology, has announced the official launch of its MiniMed™ 780G system in the U.S., which now works with the Instinct sensor made by Abbott. The system was approved by the FDA earlier this year and is now available for customers across the U.S. This is an important step forward in diabetes care, providing a smarter and simpler way for people to manage their diabetes.
The Instinct sensor is one of the smallest and thinnest continuous glucose monitoring (CGM) sensors available, and it can be worn for up to 15 days. When used with the MiniMed™ 780G system, the sensor automatically adjusts insulin levels every five minutes based on real-time glucose readings, helping people with diabetes spend less time managing their condition.
This new sensor adds to Medtronic’s range of options, including the Simplera Sync™ sensor and the Guardian™ 4 sensor, all part of a growing collection of products designed to make managing diabetes easier and more personalized.
According to Coherent Market Insights, the Digital Diabetes Management Market is projected to grow at a CAGR of 22.5% during 2025 to 2032. Currently, the market is at USD 13.97 Billion in 2025 and is expected to be around USD 57.83 Billion by 2032. The global digital diabetes management market is experiencing strong growth owing to the increasing prevalence of diabetes and growing geriatric population around the world. Moreover, the advent of Artificial Intelligence (AI) in diabetes management devices and increasing demand for digital diabetes management devices is expected to boost the growth of the market.
"Bringing together the Instinct sensor, made by Abbott, with the excellent algorithm of the MiniMed™ 780G system creates an extremely effective combination. With the MiniMed™ 780G system, my patients have seen improved time in range and now with the Instinct sensor it's a seamless experience," said Dr. Steve Edelman, a person living with type 1 diabetes and founder and director of Taking Control of Your Diabetes 501c3 (TCOYD.org). "Feedback from the early customer pilot program has been very positive and matches what my colleagues and I are seeing in our clinics. I'm thrilled that the Instinct sensor is now available so that more people living with type 1 diabetes will get access to this life-changing technology improving their day-to-day experience dealing with this difficult condition."
"This milestone marks an important next step in our work to bring the proven clinical outcomes of our MiniMed™ 780G system to more people living with diabetes," said Que Dallara, EVP and president of Medtronic Diabetes. "With this launch, we're expanding a smart dosing ecosystem built for choice, so every person can find a solution that fits their life. We exist to make life with diabetes easier and more predictable, so people living with diabetes can enjoy greater freedom and better health every day. Our goal is to deliver confidence and peace of mind, so everyone—including loved ones—can live boldly without compromise."
Source:
News Release: Medtronic
Company: Medtronic
